La Merie Publishing: Market Research Reports

Product description The report “Coagulation Factors 2010 - The Portfolio Aspect as Decisive Force: A Competitive Landscape and R&D Pipeline Analysis of Hemostasis Proteins” ... but also newcomers to the field are developing more than one factor. Portfolio not only means the addition of a second or even third ...

Product description The present Competitive Intelligence Report about Tau and Amyloid Beta Targeted Therapy of Alzheimer’s Disease provides a competitor evaluation in the field of therapeutic vaccine...

... to print or export an individual report. Despite the tremendous attrition rate of PPAR agonist R&D over the last 20 years, the ones in the market ... delta) Corporate PPAR Agonist Product Portfolios and R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers ...

... and e-mail support will be provided. Benefits from the R&D Drug Pipeline Database: New database with no historical burden Intuitive use Designed for ... Targets of the Scroll Down Menu: Anti-Infective Antibodies Antibody-Drug Conjugates (ADC) Biologic & Immune Therapy of S. aureus Infections c-MET/HGF ...

... A Streptococcus Group B Streptococcus Other Streptococcal Vaccine & Antibody R&D Agreements Corporate Streptococcal Vaccines & Antibody R&D Pipelines About La Merie About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D ...

... P. aeruginosa Peptides P. Aeruginosa Small Molecules P. aeruginosa R&D Licensing Agreements Corporate P. aeruginosa Vaccines & Therapeutics R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of ...

... Merie and available in the online store during the subscription. Among La Merie reports are more than 100 Competitor Analysis reports as well ... sent to ensure customer support. Features of the Flat-Rate Online Access to La Merie Reports: 24/7 access to all La Merie reports Instant online download of report ...

... of the three recommended doses when they were younger. The approved vaccines protect against two or four, respectively, most common types ... a hyperlink leading to the source of information. Index HPV Vaccines Corporate HPV Vaccines R&D Pipelines About La Merie About Competitor Analysis Series The ...

Product description Subscription to La Merie's proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category and R&D Phase. Use of the R&D database of cancer drugs is intuitive ...

... a hyperlink leading to the source of information. Index Proteins & peptides Antibodies Vaccines Corporate R&D Pipelines of Biologic and Immuno Therapeutics of S. aureus infections About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS, but concise ...

Product description The present Brief Report about molecules targeting interleukin-17 (IL-17) or its receptor provides an assessment, competitor evaluation and detailed profiles of antibodies and other molecules in development. R&D projects of primarily antibodies targeting IL-17 or IL-17R to treat ...

... leading to the source of information. Index BlyS, BAFF & APRIL Targeted Therapy Corporate BlyS, BAFF & APRIL R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, ...

... , R&D Stage and additional comments with a hyperlink leading to the source of information. Index Notch Pathway Inhibitors Corporate Notch Pathway Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise ...

Product description Subscription to La Merie's proprietary Oncology Pipeline Database provides online access to more than 3,000 project entries in oncology. Each project is specified for its Target or Mechanism of Action, Product Category and R&D Phase. Use of the R&D database of cancer drugs is intuitive ...

... targeted therapy of prostate and other cancers. Prostate-specific antigen (PSA) was discovered more than 20 years ago and has become the ... PSA Targeted Therapy Corporate PSMA & PSA Targeted Therapy R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers ...

... Indication, R&D Stage and additional comments with a hyperlink leading to the source of information. Index Selective Estrogen Receptor Modulators Corporate SERM R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise ...

... disease Alzheimer's disease Multiple sclerosis Huntington's disease Ophthalmic diseases Various Corporate Neurotrophic Growth Factor R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of ...

... engineered peptides, antibodies, small molecules or even plasmids. Among the growth stimulators are the BMPs, GDFs, PDGF, PTH receptor agonists, ... , Dental, Cartilage and Tendon Growth Factor R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS ...

... description The present Competitive Intelligence Report about tissue growth factors provides a competitor evaluation in the field of molecules such as proteins, peptides ... as HGF, VEGF, TGF, NGF, GDF and quite a number of neurotrophic factors are under development. Apart from proteins as the classical drugs ...

Product description The present Competitive Intelligence Report about TGF-R agonists and antagonists provides a competitor evaluation in the field of transforming growth factor receptor (TGF-R) or TG...

Product description The present Competitive Intelligence Report about FGF-R agonists and antagonists provides a competitor evaluation in the field of fibroblast growth factor receptor (FGF-R) or PDGF targeting molecules for wound healing, cardiac tissue repair, bone formation or treatment of cancer as of ...

... R&D Stage and additional comments with a hyperlink leading to the source of information. Index Velcade Pipeline Proteasome Inhibitors Corporate Proteasome Inhibitor R&D Pipelines About La Merie About Competitor Analysis Series The Competitor Analysis Series delivers NO-FRILLS , but concise ...

... The present Competitive Intelligence Report about CXCR agonists and CXCR/CXCL antagonists provides a competitor evaluation in the field of chemokine receptor ... approved and marketed drug is plerixafor (AMD3100), a small molecule inhibitor of the CXCR-4/SDF-1 axis, used for stem cell mobilization. CXCR1 and ...

... subscription consists of 50 issues, the monthly of four or five issues. R&D Pipeline News Therapeutic Area Edition will keep you up-to-date with the ... , combination products, cell therapy and drug delivery products. The news are retrieved from business as well as scientific communications over all ...

... subscription consists of 50 issues, the monthly of four or five issues. R&D Pipeline News Technology Edition will keep you up-to-date with the latest ... , combination products, cell therapy and drug delivery products. The news are retrieved from business as well as scientific communications over all ...